Trinity College Dublin

Trinity College Dublin By using this website you consent to the use of cookies in accordance with the Trinity cookie policy. For more information on cookies see our cookie policy.

Profile Photo

Professor Declan McLoughlin

Academic Consultant (Psychiatry)

Academic Consultant (Trinity Inst. of Neurosciences (TCIN))

Prof McLoughlin took up the new post of Research Professor of Psychiatry on July 1, 2007. Prior to this I was a Senior Lecturer in the MRC Centre for Neurodegeneration Research at the Institute of Psychiatry, King's College London.
Dalton, VS, Kolshus, E, McLoughlin, DM, Epigenetics and depression: return of the repressed, Journal of Affective Disorders , 155, (1), 2014, p1-12 , Journal Article, PUBLISHED  TARA - Full Text  DOI
Kolshus E, Dalton VS, Ryan KM, McLoughlin DM, When less is more - microRNAs and psychiatric disorders., Acta psychiatrica Scandinavica, 129, (4), 2014, p241 - 256, Journal Article, IN_PRESS  DOI
Practical administration of ECT in, editor(s)A. Easton , The ECT Handbook., London, Royal College of Psychiatrists, 2013, [Dunne, R., McLoughlin, D.M.], Book Chapter, PUBLISHED
Agyapong VI, Milnes J, McLoughlin DM, Farren CK, Perception of patients with alcohol use disorder and comorbid depression about the usefulness of supportive text messages., Technology and health care : official journal of the European Society for Engineering and Medicine, 21, (1), 2013, p31-39 , Notes: [ PubMed ID: 23358057], Journal Article, PUBLISHED  DOI
Semkovska M, McLoughlin DM, Measuring Retrograde Autobiographical Amnesia Following Electroconvulsive Therapy: Historical Perspective and Current Issues., The journal of ECT, 29, (2), 2013, p127-133 , Journal Article, PUBLISHED  DOI
Thekiso, T.B., Heron, E.A., Masood, B., Murphy, M., McLoughlin, D.M., Kennedy, N., Mauling of the "celtic Tiger": Clinical characteristics and outcome of first-episode depression secondary to the economic recession in Ireland, Journal of Affective Disorders, 151, (2), 2013, p455-460 , Journal Article, PUBLISHED  DOI
Agyapong, V.I.O., McLoughlin, D.M., Farren, C.K., Six-months outcomes of a randomised trial of supportive text messaging for depression and comorbid alcohol use disorder, Journal of Affective Disorders, 151, (1), 2013, p100-104 , Journal Article, PUBLISHED  DOI
Ryan, K.M., O'Donovan, S.M., McLoughlin, D.M., Electroconvulsive stimulation alters levels of BDNF-associated microRNAs, Neuroscience Letters , 549, 2013, p125-129 , Journal Article, PUBLISHED  DOI
Skelly N, Schnittger RI, Butterly L, Frorath C, Morgan C, McLoughlin DM, Fearon P, Quality of care in psychosis and bipolar disorder from the service user perspective., Qualitative health research, 23, (12), 2013, p1672-85 , Journal Article, PUBLISHED  DOI
Ryan KM, O'Donovan SM, McLoughlin DM, Electroconvulsive stimulation alters levels of BDNF-associated microRNAs., Neuroscience letters, 549, 2013, p125-9 , Journal Article, PUBLISHED  DOI

Page 1 of 12
Dunne RA, McLoughlin DM, Physical treatments, Medicine , 40, 2012, p672 - 673, Notes: [ ], Journal Article, PUBLISHED
McLoughlin, DM, Vagus rules still apply., Psychological Medicine, 38, (5), 2008, p625 - 627, Journal Article, PUBLISHED
McLoughlin, DM, Review: repetitive transcranial magnetic stimulation is of unknown effectiveness in people with depression., Evidence-Based Mental Health, 6, (4), 2003, p118 - 118, Journal Article, PUBLISHED
Lovestone S, McLoughlin D., Alzheimer's disease: molecular biology and the quest for a treatment. , Care of the Elderly, 6, 1994, p149-152 , Journal Article, PUBLISHED
Cigeroglu YB, McLoughlin D., Psychotherapy training in Turkey, 1994, - 650-651, Miscellaneous, PUBLISHED


I have been investigating the neuronal signalling function of the Alzheimer's disease amyloid precursor protein (APP) and was among the first to identify the FE65 and X11 adaptor proteins as APPbinding partners. To study their functions in vivo, we have made X11 transgenic mice and have demonstrated that the X11s regulate APP processing and reduce cerebral Ab production and deposition. The neuronal X11 proteins are therefore novel therapeutic targets for Alzheimer's disease. I am now leading a research group studying behavioural and electrophysiological effects of X11- mediated reduction in cerebral Ab in an Alzheimer's animal model. On the clinical side, I have also been leading randomised controlled trials of therapeutic neuromodulation techniques (e.g. transcranial magnetic stimulation, electroconvulsive therapy) for neuropsychiatric disorders such as depression and schizophrenia. In St Patrick's Hospital and TCD, we are about to start a 5-year research programme called the EFFECT-Dep Study (enhancing the effectiveness of electroconvulsive therapy in severe depression and understanding its molecular mechanism of action). This programme is supported by a HRB Translational Research Award and its purpose is to improve ECT practice and use it to interrogate the molecular neurobiology of depression. We will carry out a definitive randomised controlled trial comparing bilateral and high-dose unilateral ECT, recruiting 140 patients with severe depression. We will also use an animal model of ECT treatment to characterise changes in global protein expression (i.e. the proteome) in both brain and blood plasma and also carry out similar studies using plasma from depressed patients recruited into the clinical trial. The results of these studies will improve clinical ECT and also help us understand better the molecular mechanism of action of ECT, as well as antidepressant drugs, and lead to identification of candidate peripheral biomarkers for depression, treatment response and depression relapse.